Therapy compliance in cases of hyperlipaemia, as measured through electronic monitors. Is a reminder calendar to avoid forgetfulness effective?;El cumplimiento terapéutico en las dislipemias medido mediante monitores electrónicos. ¿Es eficaz un calendario recordatorio para evitar los olvidos?

Atencion Primaria

Volumn 39, Issue 12, 2007, Pages 661-668

  Márquez Contreras, Emilio ^a,c   Casado Martínez, José Joaquín ^a   Carrasco, Juan Motero ^b   De Pablos, José Luis Martín ^a   Chaves González, Rosa ^a   Ruiz, Carmen Losada ^a   Vilas, José Carlos Pastoriza ^b  

^a Centro de Salud La Orden   (Spain)

^b MEDICINA FAMILIAR Y COMUNITARIA   (Spain)

^c Centro de Salud Adoratrices ^*  (Spain)

Author keywords

Hyperlipidaemia; Intervention; Therapeutics compliance

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ARTICLE; ELECTRONIC MEDICAL RECORD; HUMAN; HYPERLIPIDEMIA; PATIENT COMPLIANCE; RANDOMIZATION; REMINDER SYSTEM;

EID: 37349057091     PISSN: 02126567     EISSN: 15781275     Source Type: Journal    
DOI: 10.1157/13113960     Document Type: Article

References (35)

1. Rodríguez Roca G, Llisterri JL, Barrios V, Alonso Moreno FJ, Banegas JR, Lou S, et al. Grado de control de las dislipemias en los pacientes dislipémicos españoles atendidos en atención primaria. Estudio LIPICAP. Clin Invest Arterioscleros. 2006;18:226-38.
2. García Ruiz FJ, Marín Ibánez A, Pérez- Jiménez F, Pinto X, Nocea G, Ahumada C, et al. Current lipid management and low cholesterol goal attainment in common daily practice in Spain. The REALITY Study. Pharmacoeconomics. 2004;22 Suppl 3:1-12.
3. Márquez Contreras E, Casado Martínez JJ, Márquez Cabeza JJ. Estrategias para mejorar el cumplimiento. FMC. 2001;8:558-73.
4. Márquez Contreras E, Casado Martínez JJ, López de Andrés M, Corés Prieto E, López Zamorano JM, Moreno García JP, et al. Cumplimiento terapéutico de las dislipemias. Ensayo sobre la eficacia de la educación sanitaria. Aten Primaria. 1998;22:79-84.
5. Piñeiro F, Gil V, Donis M, Orozco D, Pastor R, Merino J. Relación entre el cumplimiento del tratamiento farmacológico y el grado de control en pacientes con hipertensión arterial, diabetes no insulinodependiente y dislipemias. Med Clin (Barc). 1998;111:565-7.
6. Piñeiro F, Gil V, Pastor R, Donis M, Torres MT, Merino J. Factores implicados en el cumplimiento del tratamiento farmacológico en las dislipemias. Aten Primaria. 1998;21:425-30.
7. Mora C, Gil VF, Tortajada JL, Cerdá V, Merino J. Las fases de cambio conductual como método indirecto en la valoración del incumplimiento terapéutico en las dislipemias. Med Clin (Barc). 2001;116 Supl 2:131-6.
8. Jover JL, Gil VF, Tortajada JL, Mora C, Giner C, Merino J. Efecto de la entrevista motivacional sobre la cumplimentación de la terapéutica farmacológica en pacientes con dislipemia. Med Clin (Barc). 2001;116 Supl 2:137-40.
9. García Navarro MD, Orozco Beltrán D, Gil Guillén V, Carratalá Munuera C, Terol Moltó C, Merino Sánchez J. Relación entre cumplimiento farmacológico y grado de control en pacientes con hipertensión, diabetes o dislipemias. Med Clin (Barc). 2001;116 Supl 2:141-6.
10. Márquez Contreras E, Casado Martínez JJ. Eficacia de una tarjeta sanitaria en el cumplimiento terapéutico de las dislipemias. 7.a Reunión Nacional de la Asociación de la Sociedad Española de hipertensión y Liga Española para la Lucha contra la HTA. Torremolinos, 2001. Libro Abstracts. Hipertensión; 2001.
11. Márquez Contreras E, Casado Martínez JJ, Corchado Albalat Y, Chaves González R, Grandio A, Losada Velasco C, et al. Eficacia de la llamada telefónica en el cumplimiento terapéutico de las dislipemias. Aten Primaria. 2004;33:443-50.
12. Lipid Research Clinics. The Lipid Research Clinics Coronary Primary Prevention Trial Results II. The relationships of reduction in incidence of coronary heart disease to cholesterol lowering. The effect of poor compliance and treatment side effects on sample size requirements in randomized clinical trials. J Biopharmac Statist. 1994;4:223-32.
13. Maenpäa H, Heinonen OP, Manninen V. Medication compliance and serum lipid changes in the Helsinki Heart Study. Br J Clin Pharmac. 1991;32:409-15.
14. Perreault S, Blais L, Dragomir A, Bouchard MH, Lalonde L, Laurier C, et al. Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease. Eur J Clin Pharmacol. 2005;61:667-74.
15. Caspard H, Chan AK, Walker AM. Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. Clin Ther. 2005;27:1639-46.
16. Blackburn DF, Dobson RT, Blackburn JL, Wilson TW. Cardiovascular morbidity associated with nonadherence to statin therapy. Pharmacotherapy. 2005;25:1035-43.
17. Peterson AM, Takiya L, Finley R. Meta-analysis of interventions to improve drug adherence in patents with hyperlipidemia. Pharmacotherapy. 2003;23:80-7.
18. Gil Guillén VF, Orozco Beltrán D, Quirce Andrés F, Merino Sánchez J. Aplicación práctica de la estadística. En: Tratado de epidemiología clínica. II Departamento de Medicina y Psiquiatría. Universidad de Alicante. Madrid: Cyma Duphont-Pharma; 1995. p. 101-58.
19. Ministerio de Sanidad y Consumo, Sociedad Española de Cardiología y Sociedad Española de Arteriosclerosis. Control de la Colesterolemia en España, 2000: un instrumento para la prevención cardiovascular. Clin Invest Arterioscleros. 2000;12:125-52.
20. Executive Summary of the Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment oh High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-97.
21. Avorn J, Monette J, Lanour A, Horda PHD, Bohn L, Monane M, et al. Persistencia en el uso de medicaciones hipolipemiantes. JAMA (ed esp). 1998;7:390-6.
22. Cheng CW, Woo KS, Chan JC, Tomlinson B, You JH. Association between adherence to statin therapy and lipid control in Hong Kong Chinese patients at high risk of coronary heart disease. Br J Clin Pharmacol. 2004;58:528-35.
23. Lachaine J, Rinfret S, Merikle EP, Tarride JE. Persistence and adherence to cholesterol lowering agents: evidence from Regie de l'Assurance Maladie du Quebec data. Am Heart J. 2006;152:164-9.
24. Valdez CA, Ulrich H. Similar medication compliance and control of dyslipidemia with simvastatin or atorvastatin in a staff-model HMO medical clinic. J Manag Care Pharm. 2005;11:499-504.
25. Kopjar B, Sales AE, Pineros SL, Sun H, Li YF, Hedeen AN. Adherence with statin therapy in secondary prevention of coronary heart disease in veterans administration male population. Am J Cardiol. 2003;92:1106-8.
26. Faulkner MA, Wadibia EC, Lucas BD, Hilleman DE. Impact of pharmacy counseling on compliance and effectiveness of combination lipid-lowering therapy in patients undergoing coronary artery revascularization:a randomized, controlled trial. Pharmacotherapy. 2000;20:410-6.
27. Brown BG, Bardsley J, Puolin D. Moderate dose, three drug therapy with niacin, lovastatin and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary heart disease. Am J Cardiol. 1997;80:111-5.
28. Vrijens B, Belmans A, Matthys K, De Klerk E, Lesaffre E. Effect of intervention through a pharmaceutical care program on patient adherence with prescribed once-daily atorvastatin. Pharmacoepidemiol Drug Saf. 2006;15:115-21.
29. Lee Jk, Grace KA, Taylor AJ. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and low-density lipoprotein cholesterol: a randomized controlled trial. JAMA. 2006;296:2614-6.
30. Burke LE, Dunbar-Jacob J, Orchard TJ, Sereikaa SM. Improving adherence to a cholesterol-lowering diet: a behavioral intervention study. Patient Educ Couns. 2005;57:134-42.
31. Gibson TB, Mark TL, Axelsen K, Baser O, Rublee DA, McGuigan KA. Impact of statin copayments on adherence and medical care utilization and expenditures. Am J Manag Care. 2006;12 Suppl 12:11-9.
32. Thiebaud P, Patel BV, Nichol MB, Berenbeim DM. The effect of switching on compliance and persistence: the case of statin treatment. Am J Manag Care. 2005;11:670-4.
33. Shrank WH, Hoang T, Ettner SL, Glassman PA, Nair K, DeLapp D, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-7.
34. Benner JS, Tierce JC, Ballantyne CM, Prasad C, Bullano MF, Willey VJ, et al. Follow-up lipid tests and physician visits are associated with improved adherence to statin therapy. Pharmacoeconomics. 2004;22 Suppl 3:13-23.
35. Benner JS, Pollack MF, Smith TW, Bullano MF, Willey VJ, Williams SA. Association between short-term effectiveness of statins and long-term adherence to lipid-lowering therapy. Am J Health Syst Pharm. 2005;62:1468-75.